Diagnose af livstruende nekrotiserende blødt vævsinfektioner (NSTI) ved hjælp af indocyaningrøn (ICG) kinetisk modellering
Necrotizing soft-tissue infections (NSTIs, a.k.a. "necrotizing fasciitis" or "flesh-eating bacteria") are aggressive infections that can progress rapidly from mild symptoms to sepsis, multi-organ failure, and death. NSTI cases present with non-specific clinical, imaging, and laboratory findings, and standard-of-care techniques for NSTI diagnosis lack sensitivity and specificity, resulting in frequent misdiagnosis and delayed care, which is the single most important predictor of survival. Consequently, the cumulative mortality rate for patients with NSTIs is 20- 30%; a dire need exists for more accurate and rapid detection of NSTIs. Fluorescence-guided surgery is a nascent technology seeking to improve the recognition of anatomical structures and disease processes using fluorescent probes (fluorophores). Indocyanine green (ICG) is an FDA-approved, near-infrared fluorophore with a >60-year safety record for vascular perfusion assessment. A distinguishing histological feature of NSTIs is prominent blood vessel thrombosis in affected tissues. Leveraging these pro-thrombotic effects, our study group has demonstrated in a first-in-human study (NCT04839302) that intravenous administration of ICG and immediate fluorescence imaging reveals prominent signal deficits in NSTI-positive tissues that differentiate significantly with increased signal seen with more common-and less virulent-infections such as cellulitis. We seek now to evaluate this imaging technique on a broader scale and determine if our findings are consistent for patients affected by NSTI-causing pathogens that are not endemic to our region. This prospective, observational, multicenter clinical study will involve video-rate ICG fluorescence imaging of patients suspected of having NSTIs who present to eight tertiary, Level 1 medical centers across the United States (Aim 1). Using dynamic contrast-enhanced fluorescence imaging (DCE-FI), time profiles of ICG fluorescence intensity from different tissue pixels/regions will be extracted and parameterized to extract first-pass kinetic features. These DCE-FI features, which characterize tissue perfusion, will be evaluated alone and in combination with anonymized electronic medical record data to create a DCE-FI-based clinical decision tool and a machine- learning-based fusion (DCE FI+lab/imaging data) tool; these will be compared to identify the most accurate means of diagnosing NSTIs (Aim 2). The best-performing tool will then be evaluated-compared to current diagnostic tests-in a prospective observational clinical study of patients presenting to tertiary emergency departments with findings concerning for NSTIs (Aim 3). Based on our human study, fluorescence imaging will not delay current standard of care. To ensure data fidelity, all sites will use similar: 1) commercial fluorescence imaging systems and accessories; and 2) validated commercial fluorescence reference phantoms. Based on our early results, we have strong confidence that following rigorous testing, ICG DCE-FI will lead to an entirely new methodology for rapid identification of patients with NSTIs, which will ultimately reduce patient morbidity and improve survival.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Eric R Henderson, MD
- Telefonnummer: 603-650-5133
- E-mail: Eric.R.Henderson@hitchcock.org
Undersøgelse Kontakt Backup
- Navn: Morgan T Mazanec, MPH
- Telefonnummer: 603-308-9233
- E-mail: Morgan.T.Mazanec@Hitchcock.ORG
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- University of California, Los Angeles
-
Ledende efterforsker:
- Christopher Lee, MD
-
Kontakt:
- Christopher Lee, MD
- Telefonnummer: 310-319-1234
- E-mail: ChristopherLee@mednet.ucla.edu
-
Underforsker:
- Nicholas Bernthal, MD
-
Stanford, California, Forenede Stater, 94305
- Rekruttering
- Stanford University
-
Ledende efterforsker:
- Joseph Forrester, MD
-
Kontakt:
- Joseph Forrester, MD
- E-mail: jdf1@stanford.edu
-
Underforsker:
- Ariel Knight, MD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University/Grady Memorial Hospital
-
Kontakt:
- Morgan Fuller
- Telefonnummer: (404) 251-8953
- E-mail: jaimo.ahn@emory.edu
-
Ledende efterforsker:
- Jaimo Ahn, MD, PhD
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48104
- Rekruttering
- University of Michigan
-
Kontakt:
- Molly Hunter, MD
- E-mail: huntmary@med.umich.edu
-
Ledende efterforsker:
- Molly Hunter, MD
-
Ledende efterforsker:
- Raymond Jean, MD
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Rekruttering
- Dartmouth-Hitchcock Medical Center
-
Kontakt:
- Eric R Henderson, MD
- Telefonnummer: 603-650-5133
- E-mail: Eric.R.Henderson@hitchcock.org
-
Underforsker:
- Jonathan Elliot, PhD
-
Underforsker:
- Samuel S Streeter, PhD
-
Underforsker:
- Macgregor Montano, PharmD
-
Underforsker:
- Scott Rodi, MD
-
Ledende efterforsker:
- Eric R Henderson, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania
-
Kontakt:
- Niels Martin, MD, PhD
- E-mail: Niels.Martin@pennmedicine.upenn.edu
-
Ledende efterforsker:
- Niels Martin, MD, PhD
-
Underforsker:
- Sunil Singhal, MD, PhD
-
Underforsker:
- Jane Keating, MD
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- Rekruttering
- University of Pittsburgh Medical Center
-
Kontakt:
- Kurt Weiss, MD
- Telefonnummer: (412) 802-4137
- E-mail: weiskr@UPMC.EDU
-
Ledende efterforsker:
- Kurt Weiss, MD
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37235
- Rekruttering
- Vanderbilt University
-
Kontakt:
- Jonathan Schoenecker, MD, PhD
- Telefonnummer: (615) 936-3391
- E-mail: jon.schoenecker@vumc.org
-
Ledende efterforsker:
- Jonathan Schoenecker, MD, PhD
-
Underforsker:
- William Obremskey, MD
-
Underforsker:
- Eben Rosenthal, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients presenting to the ED or clinic who are considered at intermediate- or high-risk for NSTI.
Beskrivelse
Inclusion Criteria:
- Age ≥18 years.
- Clinical suspicion of NSTI based on the local standard of care warranting:
- Hospital admission for observation due to suspected NSTI; and/or
- Soft tissue biopsy to rule in/out suspected NSTI; and/or
- Surgical debridement for suspected NSTI; and/or
- Specific institutional threshold criteria for triggering NSTI work-up; and
- Ability to give written informed consent.
Exclusion Criteria:
- History of allergy to ICG and/or iodine.
- Pregnant women or nursing mothers.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Determine if tissue perfusion, determined by first-pass ICG fluorescence kinetics, is reliably reduced in the setting of a necrotizing infection compared to a non-necrotizing infection.
Tidsramme: From enrollment to the end of fluorescence imaging (about 1 day)
|
We will evaluate first-pass fluorescence signal intensity changes from indocyanine green (ICG), a vascular perfusion fluorophore, in the setting of severe soft-tissue infections to determine if ICG fluorescence may be an accurate and reliable diagnostic test for differentiating life-threatening necrotizing infections from non-life-threatening non-necrotizing infections. |
From enrollment to the end of fluorescence imaging (about 1 day)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Determine if first-pass ICG fluorescence kinetics in patients with necrotizing infections vary based on the causative bacterial species.
Tidsramme: From enrollment to the end of imaging and lab results (about 30 days)
|
In patients who had a documented necrotizing soft-tissue infection, we will compare first-pass fluorescence signal intensity changes from ICG based on the predominant causative bacterial species isolated from a patient's infection to determine if ICG signal changes vary by species. |
From enrollment to the end of imaging and lab results (about 30 days)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 02002719
- 1R01AI184513-01 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Data will only be shared in aggregate.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .